Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Year: 2025
Type: other
Abstract: Merestinib and LY2874455 inhibit MET-activated signal transduction. A, AML cell lines treated with merestinib and LY2874455 in vitro for 1 hour exhibited decreased levels of pSTAT3 and pSTAT5 by phospho-flow cytometry. Standard errors are shown for KG1a (n=3) and HEL (n=2) cell lines. Representative flow cytometry histograms are shown in B. Reverse transcription-PCR showing decreased expression of CISH, a downstream target of STAT5, is displayed in C. Abbreviations: U = unstained; FGFRi = the FGFR inhibitor LY2874455.
Authors: Evan C. Chen, Helen Gandler, Isidora Tošić, Geoffrey G. Fell, Ashlee Fiore, Olga Pozdnyakova, Daniel J. DeAngelo, Ilene Galinsky, Marlise R. Luskin, Martha Wadleigh, Eric S. Winer, Rebecca Leonard, Kelsey O'Day, Adrienne de Jonge, Donna Neuberg, A. Thomas Look, Richard M. Stone, David A. Frank, Jacqueline S. Garcia
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416671900
Cites:
Cited by:
Related to: